A clinical trial update was recorded on August 28, 2026, for study NCT03457948. The trial, titled "Pembrolizumab With Liver-Directed or Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors and Liver Metastases," is a Phase 2 study. Its status is listed as COMPLETED as of this update.
The study evaluated pembrolizumab in combination with liver-directed therapy or peptide receptor radionuclide therapy in patients with neuroendocrine tumors and liver metastases. Peptide receptor radionuclide therapy relies on somatostatin-based analogs to target somatostatin receptors expressed on neuroendocrine tumor cells. Somatostatin itself remains classified as an unapproved compound used in research contexts.
No outcome data, efficacy results, or safety findings are included in this update. The record only reflects a change in trial status to completed, along with the associated phase and title as registered. Readers should consult the original clinical trial registry entry for further details on the study design, enrollment, or any future posting of results.
For general background on somatostatin and its role in research settings, readers can refer to the compound overview.